UA116889C2 - Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc) - Google Patents
Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)Info
- Publication number
- UA116889C2 UA116889C2 UAA201500254A UAA201500254A UA116889C2 UA 116889 C2 UA116889 C2 UA 116889C2 UA A201500254 A UAA201500254 A UA A201500254A UA A201500254 A UAA201500254 A UA A201500254A UA 116889 C2 UA116889 C2 UA 116889C2
- Authority
- UA
- Ukraine
- Prior art keywords
- isoforms
- mixture
- composition
- pharmaceutical composition
- apg101
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12176978 | 2012-07-18 | ||
| EP12176980 | 2012-07-18 | ||
| PCT/EP2013/065250 WO2014013039A1 (en) | 2012-07-18 | 2013-07-18 | Composition comprising a mixture of cd95-fc isoforms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA116889C2 true UA116889C2 (uk) | 2018-05-25 |
Family
ID=48794121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201500254A UA116889C2 (uk) | 2012-07-18 | 2013-07-18 | Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc) |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US9434783B2 (enExample) |
| EP (4) | EP2875044B1 (enExample) |
| JP (2) | JP6231562B2 (enExample) |
| KR (1) | KR102201694B1 (enExample) |
| CN (3) | CN104640876A (enExample) |
| AU (2) | AU2013291984B2 (enExample) |
| BR (1) | BR112015000732B1 (enExample) |
| CA (2) | CA2877989C (enExample) |
| DK (2) | DK2875045T3 (enExample) |
| ES (2) | ES2674662T3 (enExample) |
| HK (1) | HK1207095A1 (enExample) |
| IL (1) | IL236659A (enExample) |
| MX (1) | MX371430B (enExample) |
| NZ (1) | NZ703546A (enExample) |
| RU (2) | RU2648157C2 (enExample) |
| SG (1) | SG11201500134QA (enExample) |
| UA (1) | UA116889C2 (enExample) |
| WO (2) | WO2014013037A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2877989C (en) * | 2012-07-18 | 2021-05-25 | Apogenix Gmbh | Shortened cd95-fc variants |
| MX363679B (es) * | 2013-04-29 | 2019-03-29 | Apogenix Ag | Metodo para diagnosticar cancer. |
| NO2776305T3 (enExample) | 2014-04-23 | 2018-01-27 | ||
| EP3137909B1 (en) | 2014-04-29 | 2018-06-06 | Apogenix AG | Diagnostic anti-cd95l antibody |
| US9587215B2 (en) | 2014-08-07 | 2017-03-07 | General Electric Company | Devices, systems and methods for automated transfer of a sample |
| US20160176921A1 (en) * | 2014-12-22 | 2016-06-23 | Alexion Pharmaceuticals, Inc. | Methods of purifying recombinant proteins |
| CA3134144A1 (en) | 2019-03-29 | 2020-10-08 | Myst Therapeutics, Llc | Ex vivo methods for producing a t cell therapeutic and related compositions and methods |
| KR20220122639A (ko) | 2019-11-27 | 2022-09-02 | 미스트 쎄라퓨틱스, 엘엘씨 | 조절제를 이용한 종양 반응성 t 세포 조성물의 제조 방법 |
| JP7737374B2 (ja) * | 2019-12-12 | 2025-09-10 | イー・エム・デイー・ミリポア・コーポレイシヨン | 透析濾過緩衝液を用いて増強したウイルス濾過 |
| WO2021174208A1 (en) | 2020-02-27 | 2021-09-02 | Myst Therapeutics, Llc | Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof |
| KR102898622B1 (ko) * | 2020-04-10 | 2025-12-12 | 악스톤 바이오사이언시스 코퍼레이션 | Covid-19 융합 단백질에 대한 항원 특이적 면역요법 및 사용 방법 |
| CN115894706A (zh) * | 2021-09-30 | 2023-04-04 | 北京康辰药业股份有限公司 | 靶向PD-L1和FasL的融合蛋白、核苷酸序列及其应用 |
| WO2026044087A1 (en) | 2024-08-21 | 2026-02-26 | Shape Therapeutics Inc. | Increased cellular stability for aav production |
| WO2026073032A1 (en) | 2024-09-27 | 2026-04-02 | Shape Therapeutics Inc. | Constructs for improved aav production |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997042319A1 (en) * | 1996-05-02 | 1997-11-13 | Mochida Pharmaceutical Co., Ltd. | NOVEL Fas ANTIGEN DERIVATIVES |
| ATE273713T1 (de) * | 1996-10-31 | 2004-09-15 | Mochida Pharm Co Ltd | Fas-antagonist für die prophylaxe oder therapie von gvhd |
| KR20000075749A (ko) | 1997-02-27 | 2000-12-26 | 오노 야꾸힝 고교 가부시키가이샤 | 신규의 폴리펩티드, 그 폴리펩티드를 암호하는 ｄｎａ 및 그용도 |
| US6905684B1 (en) * | 1997-11-10 | 2005-06-14 | Mochida Pharmaceutical Co., Ltd. | Preventives and remedies for diffuse lung diseases |
| CN101684158A (zh) * | 2001-01-17 | 2010-03-31 | 特鲁比昂药品公司 | 结合域-免疫球蛋白融合蛋白 |
| EP1273297A1 (en) * | 2001-07-06 | 2003-01-08 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Vitamin E for the treatment of diseases in which the binding of the transcription factor NF-KB and/or AP-1 to promoter target sites has a beneficial effect (eg AIDS, cardiac infarction) |
| DK1606318T3 (da) * | 2003-03-26 | 2009-11-02 | Apogenix Gmbh | Forbedrede Fc-fusionsproteiner |
| WO2007109857A1 (en) * | 2006-03-28 | 2007-10-04 | Biopharmica Ltd | Agent for the treatment of hormone-dependent disorders and uses thereof |
| EP2041576B1 (en) * | 2006-06-21 | 2011-08-10 | Apogenix GmbH | Differential cytokine expression in human cancer |
| DK2101877T3 (da) * | 2006-12-28 | 2013-09-23 | Deutsches Krebsforsch | Neutralisering af virkningen af CD95 til blokering af invasion af glioblastomceller in vivo |
| WO2008101671A2 (en) * | 2007-02-19 | 2008-08-28 | Apogenix Gmbh | Il-4 fc fusion proteins |
| EP2009022A1 (en) * | 2007-06-26 | 2008-12-31 | Apogenix GmbH | Trimeric death ligands with enhanced activity (tenascin) |
| ES2524553T3 (es) * | 2008-06-17 | 2014-12-10 | Apogenix Gmbh | Receptores multiméricos de TNF |
| ES2593049T3 (es) * | 2009-01-09 | 2016-12-05 | Apogenix Ag | Proteínas de fusión que forman trímeros |
| WO2011010156A1 (en) * | 2009-07-21 | 2011-01-27 | Queen Mary & Westfield College | Fas (apo-1, cd95) targeted platforms for intracellular drug delivery |
| CN102770458A (zh) * | 2009-12-02 | 2012-11-07 | 阿塞勒隆制药公司 | 用于增加Fc融合蛋白的血清半寿期的组合物和方法 |
| CA2877989C (en) * | 2012-07-18 | 2021-05-25 | Apogenix Gmbh | Shortened cd95-fc variants |
| MX363679B (es) * | 2013-04-29 | 2019-03-29 | Apogenix Ag | Metodo para diagnosticar cancer. |
-
2013
- 2013-07-18 CA CA2877989A patent/CA2877989C/en not_active Expired - Fee Related
- 2013-07-18 JP JP2015522107A patent/JP6231562B2/ja active Active
- 2013-07-18 EP EP13737631.5A patent/EP2875044B1/en not_active Not-in-force
- 2013-07-18 SG SG11201500134QA patent/SG11201500134QA/en unknown
- 2013-07-18 HK HK15107778.6A patent/HK1207095A1/xx unknown
- 2013-07-18 AU AU2013291984A patent/AU2013291984B2/en active Active
- 2013-07-18 CA CA2878992A patent/CA2878992C/en active Active
- 2013-07-18 CN CN201380043661.6A patent/CN104640876A/zh active Pending
- 2013-07-18 WO PCT/EP2013/065248 patent/WO2014013037A1/en not_active Ceased
- 2013-07-18 UA UAA201500254A patent/UA116889C2/uk unknown
- 2013-07-18 BR BR112015000732-5A patent/BR112015000732B1/pt active IP Right Grant
- 2013-07-18 EP EP13742412.3A patent/EP2875045B1/en active Active
- 2013-07-18 ES ES13742412.3T patent/ES2674662T3/es active Active
- 2013-07-18 EP EP18166228.9A patent/EP3406630B1/en not_active Not-in-force
- 2013-07-18 RU RU2015105328A patent/RU2648157C2/ru active
- 2013-07-18 CN CN201380038208.6A patent/CN104662039B/zh not_active Expired - Fee Related
- 2013-07-18 WO PCT/EP2013/065250 patent/WO2014013039A1/en not_active Ceased
- 2013-07-18 CN CN201910254827.8A patent/CN109897115A/zh active Pending
- 2013-07-18 AU AU2013291982A patent/AU2013291982B2/en not_active Ceased
- 2013-07-18 JP JP2015522106A patent/JP6317739B2/ja not_active Expired - Fee Related
- 2013-07-18 DK DK13742412.3T patent/DK2875045T3/en active
- 2013-07-18 RU RU2015105330A patent/RU2648146C2/ru active
- 2013-07-18 US US14/415,871 patent/US9434783B2/en not_active Expired - Fee Related
- 2013-07-18 NZ NZ703546A patent/NZ703546A/en unknown
- 2013-07-18 DK DK18164139.0T patent/DK3409686T3/da active
- 2013-07-18 KR KR1020157004183A patent/KR102201694B1/ko active Active
- 2013-07-18 MX MX2015000731A patent/MX371430B/es active IP Right Grant
- 2013-07-18 ES ES18164139T patent/ES2924109T3/es active Active
- 2013-07-18 EP EP18164139.0A patent/EP3409686B1/en active Active
- 2013-07-18 US US14/415,866 patent/US9315570B2/en active Active
-
2015
- 2015-01-11 IL IL236659A patent/IL236659A/en active IP Right Grant
-
2016
- 2016-04-18 US US15/131,219 patent/US9657083B2/en active Active
- 2016-08-17 US US15/239,127 patent/US9908928B2/en not_active Expired - Fee Related
-
2018
- 2018-02-22 US US15/902,175 patent/US10370441B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20180103A1 (ar) | مركب صيدلاني | |
| PH12016500094A1 (en) | Autotaxin inhibitors | |
| TN2015000278A1 (en) | Autotaxin inhibitors | |
| PH12016501151A1 (en) | Nrf2 regulators | |
| PH12014502010A1 (en) | Bispecific antibodies against human tweak and human il17 and uses thereof | |
| EA201400833A1 (ru) | Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| EA033374B1 (ru) | Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения | |
| UY33735A (es) | Compuestos antivirales | |
| MD20150091A2 (ro) | Compuşi antivirali | |
| MY173521A (en) | Trpv4 antagonists | |
| JOP20140114B1 (ar) | مركبات حلقية غير متجانسة واستخداماتها | |
| UA116999C2 (uk) | Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить | |
| EA201300388A1 (ru) | Соединения замещенного бензамида | |
| MX2020001756A (es) | Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos. | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| EA201600124A1 (ru) | Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| GEP201706621B (en) | Benzamides | |
| MD20170048A2 (ro) | Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia | |
| EA201491281A1 (ru) | КОМПОЗИЦИЯ В ФОРМЕ СУХОГО ПОРОШКА, СОДЕРЖАЩАЯ КОРТИКОСТЕРОИД И β-АДРЕНЕРГИЧЕСКОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, ДЛЯ ВВЕДЕНИЯ ИНГАЛЯЦИЕЙ | |
| NZ710291A (en) | 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions | |
| MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
| MX2015011109A (es) | Composiciones estables de activador de glucoquinasa. | |
| EA201400623A1 (ru) | Новые 2h-индазолы в качестве антагонистов рецептора ep | |
| MX2016008369A (es) | Composicion farmaceutica que incluye palonosetron. | |
| MY165075A (en) | Pharmaceutical composition comprising fimasartan and hydrochlorothiazide |